1) locally advanced cervical cancer
局部晚期宫颈癌
1.
Relationship between ERCC1,XPC proteins and curative effect of neoadjuvant chemotherapy in locally advanced cervical cancers;
局部晚期宫颈癌细胞中XPC、ERCC1的表达与新辅助化疗疗效的关系
2.
To study the correlation of the expression of Bax protein before and after neoadjuvant chemotherapy with clinical effect, the expression of Bax protein was evaluated in tumor samples by immunohistochemistry in 23 patients with locally advanced cervical cancer before and after neoadjuvant intraarterial chemotherapy.
探讨Bax蛋白与宫颈癌新辅助化疗疗效之间的关系,用免疫组化方法检测23例局部晚期宫颈癌组织新辅助化疗前后Bax蛋白的表达。
3.
Objective To evaluate clinical effects of neoadjuvant intra-arterial chemotherapy for locally advanced cervical cancer.
方法选择2000年2月至2003年2月在本院确诊为局部晚期宫颈癌Ⅰb_2～Ⅱb期,并符合经动脉新辅助化疗+手术治疗适应证的患者86例为研究对象。
2) advanced cervical cancer
晚期宫颈癌
1.
Randomized clinical trial of radiotherapy combined with chemotherapy of advanced cervical cancer.;
放、化疗联合治疗晚期宫颈癌的临床研究
2.
Objective To observe the effect of combination of DDP with radiotherapy in treating the patients with advanced cervical cancer.
观察顺铂和放疗在治疗晚期宫颈癌中的作用。
3) advanced cervical cancer
中晚期宫颈癌
1.
Clinical analysis of taxol plus cisplatin concurrent with radiotherapy for middle and advanced cervical cancer;
同步放化疗治疗中晚期宫颈癌的临床研究
2.
Clinical analysis of concurrent chemotherapy plus radiotherapy for advanced cervical cancer
同步放化疗治疗中晚期宫颈癌的疗效分析
3.
AIM: To analyze the changing of HPV DNA in cervical secretions and serum TNF-α level in patients with advanced cervical cancer before and after concurrent chemoradiotherapy.
目的:观察中晚期宫颈癌患者同步放化疗治疗前、后宫颈分泌物HPV DNA及血清TNF-α含量的变化趋势。
6) metastatic cervical carcinoma
晚期转移性宫颈癌
1.
Objective To study the efficacy and adverse effect of paclitaxel plus xeloda on metastatic cervical carcinoma.
目的探讨观察紫杉醇联合希罗达对比紫杉醇联合顺铂治疗晚期转移性宫颈癌的疗效及不良反应。
补充资料：宫颈复发癌
宫颈复发癌
多发生于晚期宫颈癌(包括局部晚期)治疗后，也有报告浸润性宫颈癌治疗后约有35%复发。复发性宫颈癌的治疗困难，预后差，是宫颈癌死亡最重要的原因。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条